Rznomics Inc. has the core competencies to meet a variety of unmet medical needs through the development of anticancer biopharmaceuticals based on RNA platform technology.
Based on innovative RNA-based biopharmaceuticals,
Rznomics aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases.